Related Experiment Video

Updated: Jun 5, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

New Perspectives on Antimicrobial Agents: Fosmanogepix

Frederic Lamoth1,2

  • 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Antimicrobial Agents and Chemotherapy
|June 4, 2026
PubMed

Insights

Fosmanogepix shows promise for treating invasive fungal infections (IFIs) due to its broad-spectrum activity, oral availability, and safety. This new antifungal agent offers hope against resistant fungal strains and various refractory infections.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) present significant mortality challenges due to limited drug options, toxicity, and emerging resistance.
  • Current antifungal therapies face limitations in efficacy and safety profiles.

Purpose of the Study:

  • To review the therapeutic potential of fosmanogepix, a novel antifungal agent, for treating IFIs.
  • To highlight fosmanogepix's broad-spectrum activity, pharmacologic properties, and potential role in combating resistant fungal pathogens.

Main Methods:

  • Literature review of preclinical and clinical data on fosmanogepix.
  • Analysis of fosmanogepix's pharmacokinetic and pharmacodynamic properties.
  • Evaluation of its efficacy against various fungal species, including resistant strains.

Main Results:

  • Fosmanogepix exhibits broad-spectrum antifungal activity against yeasts and molds.
  • It possesses favorable properties including oral bioavailability, extensive tissue distribution (including CNS), and a good safety profile with minimal drug interactions.
  • Promising results were observed in treating multidrug-resistant candidiasis, azole-resistant aspergillosis, fusariosis, and other refractory mold infections.

Conclusions:

  • Fosmanogepix represents a promising therapeutic option for various IFIs, particularly those caused by resistant organisms.
  • Its favorable characteristics position it as a valuable addition to the antifungal armamentarium.
  • Further clinical development of fosmanogepix and related gepix compounds is warranted for challenging fungal infections.
Keywords:
APX001FusariumGwt1LomentosporaScedosporium

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...